A Phase 3 interventional study of Edoxaban and ASA in Atrial High Rate Episodes, sponsored by Atrial Fibrillation Network. Terminated at 18 sites in 18 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by Atrial Fibrillation Network · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing edoxaban in Atrial Fibrillation — 5 open to participants now, 6 under way, 1 of them phase 3. edoxaban · Atrial Fibrillation.
Among the 29 studies testing edoxaban in Atrial Fibrillation, this one is the 4th largest by enrollment, is one of 2 that started in 2016, is one of 10 in phase 3, and was the 8th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →5 of the 29 studies testing edoxaban in Atrial Fibrillation are open now, in 8 countries. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Azienda Ospedaliero Universitaria Maggiore della Carita · Sites in Italy
Ages 18+
Sung-Hwan Kim · Sites in Korea, Republic of
Ages 19–79
University of Aarhus · Sites in Denmark, Finland, Germany and 2 more countries
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 80+
By country, each count listing its studies:
edoxaban: first FDA approval 2015 (SAVAYSA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 11 · Phase 4 9
First in 2007; this study’s year is marked. 2 started in 2016.
This study's enrollment of 2,608 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 536 across the 29 interventional studies. Of the 22 that completed or were terminated, 12 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 29 have an industry lead sponsor. The 10 most frequent:
Atrial Fibrillation Network is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
13 studies in Atrial Fibrillation by Atrial Fibrillation Network: 2 open now, 2 under way, none of them phase 3. Of 10 finished, 1 (10%) have results posted.
Among the 13 studies in Atrial Fibrillation by Atrial Fibrillation Network, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2016, is one of 3 in phase 3, and was the 9th registered.
Atrial Fibrillation Network’s Atrial Fibrillation studies by the year they started, since 2004.
1 of the studies testing edoxaban in Atrial Fibrillation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03129490Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing edoxaban in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Atrial Fibrillation Network’s 13 in Atrial Fibrillation:
This tab as a report to print or save as PDF → With an account.
NOAH is an investigator-initiated, prospective, parallel-group, double-blind, randomised, multi-centre trial. The objective of the trial is to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy to pre-vent stroke, systemic embolism, or cardiovascular death in patients with AHRE and at least two stroke risk factors but without AF. The trial will be conducted in several European countries.
Atrial fibrillation (AF) is a common cause of stroke, especially ischemic stroke. So far, all available data that demonstrate a beneficial effect of oral anticoagulation for stroke prevention have been collected in populations with AF documented by conventional ECG recordings. It is well established that a large proportion of AF episodes remain undiagnosed ("silent AF"), and many of these patients present with a stroke as the first clinical sign of AF. Earlier initiation of anticoagulation could prevent such events. Continuous monitoring of atrial rhythm by implanted devices could close this diagnostic gap. Pacemakers, defibrillators, and cardiac resynchronisation devices already provide automated algorithms alerting to the occurrence of highly organised atrial tachyarrhythmia episodes, also called "subclinical atrial fibrillation" or, more commonly, "atrial high rate episodes" (AHRE). Data from large prospectively followed patient cohorts demonstrated that stroke rate is increased in patients with AHRE. A sizeable portion of these patients develops clinically detected AF over time. In these patients, AHRE can be considered as an early manifestation of paroxysmal AF. A few AHRE patients do not develop clinically overt AF, and the absolute stroke rates are lower in patients with AHRE when compared to stroke rates in patients with clinically diagnosed AF. In light of the bleeding complications associated with oral anticoagulant therapy, there is thus uncertainty about the optimal antithrombotic therapy in patients with AHREs.
The Non-vitamin K antagonist Oral anticoagulants (NOACs) provide similar or slightly better stroke prevention, and appear slightly safer compared to vitamin K antagonists (VKAs). In addition, no individual therapy adjustment of NOACs has to be performed. Edoxaban, a newly introduced NOAC, at a dose regime of 60 mg once daily (OD) has a favourable profile compared to dose-adjusted VKA therapy: In the ENGAGE-TIMI 48 trial, edoxaban prevented strokes at least as effectively as VKA therapy but caused less major bleeding events than VKA therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In addition, at least one of the following cardiovascular conditions leading to a modified CHA2DS2VASc score of 2 or more:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Edoxaban will be applied in NOAH at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics: Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein-P inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole.
Drug: Edoxaban
Either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator
Drug: ASA
Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF
Also known as: Lixiana, Savaysa
ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripheral or coronary artery disease, a prior myocardial infarction, or a prior stroke.
Also known as: ASS
Composite of Stroke, Systemic Embolism, or Cardiovascular Death
Time from randomisation to the first occurrence of stroke, systemic embolism, or cardiovascular death; incidence of first occurence of outcome measure.
Time frame: 28 months
Components of the Primary Outcome, Stroke
Time from randomisation to the first occurrence of ischemic stroke; incidence of first occurence of outcome measure.
Time frame: 28 months
Major Adverse Cardiac Events (MACEs: Cardiac Death, Myocardial Infarction, Acute Coronary Syndrome (ACS)
PCI, CABG
Time frame: 28 months
All-cause Death
All-cause death
Time frame: 28 months
Major Bleeding Events
according to the International Society on Thrombosis and Haemostasis (ISTH) definitions
Time frame: 28 months
Quality of Life Changes at 12 and 24 Months Compared to Baseline
Adjusted mean change from baseline at 12 and 24 months of Quality of life as assessed by the EuroQol Group 5-Dimension 5-Level questionnaire (EQ-5D-5L): The resulting score of the UK index ranges from 1 (for the best state) to - 0.285 (for the worst state), with 5.1% of the states valued as worse than dead. EQ5D- VAS: visual-analogue scale (0 worst to 100 best). Subscales of the UK index score were combined by adding up EQ-5D-5L index values with STATA using the English (ENG) Devlin value set, Version 1.1 (Updated 01/12/2020). Karnofsky Performance Scale is an 11-point scale from 0 to 100 (0 worst to 100 best).
Time frame: Baseline, 12 months and 24 months.
Patient Satisfaction at 12 and 24 Months Compared to Baseline
Adjusted change from baseline at 12 and 24 months measured by the Perception of Anticoagulant Treatment Questionnaire: For convenience score, a 0 - 100 scale; for satisfaction score a 0 - 100 scale; for both scores, the higher the score, the higher the convenience/satisfaction.
Time frame: Baseline, 12 months and 24 months.
Cost Effectiveness and Health Resource Utilisation
estimated by quantification of relevant events, interventions, nights spent in hospital and cardiovascular therapies
Time frame: 28 months
Autonomy Status
Autonomy status only in patients with stroke during study participation, assessed at 24 month by modified Rankin scale. (Score ranges from 1 to 8, a higher score indicates a higher grade of disability)
Time frame: Baseline and 24 months
Components of the Primary Outcome, Systemic Embolism
Time from randomisation to the first occurrence of systemic embolism; incidence of first occurence of outcome measure.
Time frame: 28 months
Components of the Primary Outcome, Cardiovascular Death
Time from randomisation to the first occurrence of cardiovascular death; incidence of first occurence of outcome measure.
Time frame: 28 months
| Milestone | Edoxaban | ASA or Placebo |
|---|---|---|
| Started | 1306 | 1302 |
| Completed | 500 | 472 |
| Not completed | 806 | 830 |
Time from randomisation to the first occurrence of stroke, systemic embolism, or cardiovascular death; incidence of first occurence of outcome measure.
| number of new events per 100 pat.-years | Edoxaban | ASA or Placebo |
|---|---|---|
| Composite of Stroke, Systemic Embolism, or Cardiovascular Death | 3.3 | 4.0 |
Time from randomisation to the first occurrence of ischemic stroke; incidence of first occurence of outcome measure.
| number of new events per 100 pat.-years | Edoxaban | ASA or Placebo |
|---|---|---|
| Components of the Primary Outcome, Stroke | 0.9 | 1.1 |
PCI, CABG
| number of new events per 100 pat.-years | Edoxaban | ASA or Placebo |
|---|---|---|
| Major Adverse Cardiac Events (MACEs: Cardiac Death, Myocardial Infarction, Acute Coronary Syndrome (ACS) | 3.6 | 4.1 |
All-cause death
| number of new events per 100 pat.-years | Edoxaban | ASA or Placebo |
|---|---|---|
| All-cause Death | 4.3 | 3.7 |
according to the International Society on Thrombosis and Haemostasis (ISTH) definitions
| number of new events per 100 pat.-years | Edoxaban | ASA or Placebo |
|---|---|---|
| Major Bleeding Events | 2.1 | 1.0 |
Adjusted mean change from baseline at 12 and 24 months of Quality of life as assessed by the EuroQol Group 5-Dimension 5-Level questionnaire (EQ-5D-5L): The resulting score of the UK index ranges from 1 (for the best state) to - 0.285 (for the worst state), with 5.1% of the states valued as worse than dead. EQ5D- VAS: visual-analogue scale (0 worst to 100 best). Subscales of the UK index score were combined by adding up EQ-5D-5L index values with STATA using the English (ENG) Devlin value set, Version 1.1 (Updated 01/12/2020). Karnofsky Performance Scale is an 11-point scale from 0 to 100 (0 worst to 100 best).
| adjusted mean change from baseline | Edoxaban | ASA or Placebo |
|---|---|---|
| EQ-5D-5L UK Index to FU12 | -0.01 (-0.03 to 0) | -0.01 (-0.02 to 0.01) |
| EQ-5D-5L UK Index to FU24 | -0.04 (-0.05 to -0.02) | -0.03 (-0.05 to -0.02) |
| EQ-5D-5L VAS to FU12 | -0.75 (-2.08 to 0.57) | -0.71 (-2.06 to 0.64) |
| EQ-5D-5L VAS to FU24 | -1.72 (-3.18 to -0.27) | -1.68 (-3.16 to 0.20) |
| Karnofsky score to FU12 | -1.14 (-1.98 to -0.31) | -1.41 (-2.26 to -0.57) |
| Karnofsky score to FU24 | -2.28 (-3.23 to -1.33) | -2.55 (-3.50 to -1.59) |
Adjusted change from baseline at 12 and 24 months measured by the Perception of Anticoagulant Treatment Questionnaire: For convenience score, a 0 - 100 scale; for satisfaction score a 0 - 100 scale; for both scores, the higher the score, the higher the convenience/satisfaction.
| scores on a scale (with 95% Confidence I | Edoxaban | ASA or Placebo |
|---|---|---|
| PACT-Q convenience to FU12 | 0.84 (-0.26 to 1.93) | 0.96 (-0.14 to 2.05) |
| PACT-Q convenience to FU24 | 1.35 (0.2 to 2.49) | 1.47 (0.32 to 2.61) |
| PACT-Q satisfaction to FU12 | 2.97 (1.36 to 4.57) | 4.01 (2.39 to 5.62) |
| PACT-Q satisfaction to FU24 | 3.80 (2.12 to 5.48) | 4.84 (3.15 to 6.52) |
estimated by quantification of relevant events, interventions, nights spent in hospital and cardiovascular therapies
Results for this outcome have not been posted.
Autonomy status only in patients with stroke during study participation, assessed at 24 month by modified Rankin scale. (Score ranges from 1 to 8, a higher score indicates a higher grade of disability)
| Scores on a scale | Edoxaban | ASA or Placebo |
|---|---|---|
| Autonomy Status | 3.0 (2.0 to 3.0) | 2.5 (2.0 to 3.0) |
Time from randomisation to the first occurrence of systemic embolism; incidence of first occurence of outcome measure.
| number of new events per 100 pat.-years | Edoxaban | ASA or Placebo |
|---|---|---|
| Components of the Primary Outcome, Systemic Embolism | 0.5 | 1.1 |
Time from randomisation to the first occurrence of cardiovascular death; incidence of first occurence of outcome measure.
| number of new events per 100 pat.-years | Edoxaban | ASA or Placebo |
|---|---|---|
| Components of the Primary Outcome, Cardiovascular Death | 2.0 | 2.2 |
Collected over (S)AEs were collected during a median follow-up time of 21 months after the baseline visit for all patients until the trial was terminated, i.e. (S)AEs were collected through study completion. (S)AEs were collected on a 6 monthly basis after baseline visit. After the announcement of early termination of the trial due to safety reasons and futility, a final visit was conducted within 3 months for all active patients including a final (Serious) Adverse Event assessment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Edoxaban | 142/1,306 (10.9%) | 498/1,306 (38.1%) | 718/1,306 (55%) |
| ASA or Placebo | 125/1,302 (9.6%) | 467/1,302 (35.9%) | 662/1,302 (50.8%) |
| Event | Edoxaban | ASA or Placebo |
|---|---|---|
| DeathGeneral disorders | 103/1306 | 87/1302 |
| Viral test negativeInvestigations | 95/1306 | 93/1302 |
| Cardiac failureCardiac disorders | 93/1306 | 90/1302 |
| PneumoniaInfections and infestations | 58/1306 | 56/1302 |
| TransfusionSurgical and medical procedures | 58/1306 | 28/1302 |
| Cardiac pacemaker replacementSurgical and medical procedures | 38/1306 | 57/1302 |
| Endoscopy upper gastrointestinal tractInvestigations | 54/1306 | 23/1302 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 50/1306 | 19/1302 |
| AnaemiaBlood and lymphatic system disorders | 44/1306 | 16/1302 |
| Diagnostic procedureInvestigations | 40/1306 | 16/1302 |
| Event | Edoxaban | ASA or Placebo |
|---|---|---|
| Coronavirus test positiveInvestigations | 48/1306 | 30/1302 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 48/1306 | 21/1302 |
| DizzinessNervous system disorders | 47/1306 | 46/1302 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 43/1306 | 42/1302 |
| Cardiac pacemaker replacementSurgical and medical procedures | 36/1306 | 39/1302 |
| FallInjury, poisoning and procedural complications | 32/1306 | 31/1302 |
| HaematuriaRenal and urinary disorders | 31/1306 | 8/1302 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 18/1306 | 24/1302 |
| NauseaGastrointestinal disorders | 21/1306 | 11/1302 |
| HaematomaVascular disorders | 21/1306 | 17/1302 |
| Age, Continuous(years) | Edoxaban | ASA or Placebo | Total |
|---|---|---|---|
| Mean | 77.4 ± 6.5 | 77.5 ± 6.8 | 77.5 ± 6.7 |
| Sex: Female, Male(Participants) | Edoxaban | ASA or Placebo | Total |
|---|---|---|---|
| Female | 469 | 478 | 947 |
| Male | 801 | 786 | 1587 |
| Race and Ethnicity Not Collected(Participants) | Edoxaban | ASA or Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Edoxaban | ASA or Placebo | Total |
|---|---|---|---|
| Romania | 7 | 7 | 14 |
| Hungary | 35 | 35 | 70 |
| Czechia | 6 | 6 | 12 |
| Ukraine | 179 | 172 | 351 |
| United Kingdom | 76 | 80 | 156 |
| Portugal | 13 | 12 | 25 |
| Spain | 176 | 177 | 353 |
| Greece | 4 | 3 | 7 |
| Austria | 108 | 113 | 221 |
| Netherlands | 22 | 28 | 50 |
| Sweden | 9 | 7 | 16 |
| Belgium | 15 | 8 | 23 |
| Poland | 137 | 135 | 272 |
| Denmark | 11 | 7 | 18 |
| Italy | 82 | 76 | 158 |
| Bulgaria | 9 | 12 | 21 |
| France | 41 | 41 | 82 |
| Germany | 340 | 345 | 685 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2016 to primary completion in Dec 2022, 82 months.
Results were first posted in Feb 2025, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edoxaban
Atrial Fibrillation Network